• CAR-T therapy offers a groundbreaking, personalized approach to treating Oral Squamous Cell Carcinoma (OSCC). • Genetically engineers T-cells to target OSCC cells, providing a novel, direct cancer attack method. • Identifies ErbB and MUC1 as key antigens, highlighting precise targeting for effective treatment. • Addresses challenges with strategies like combination therapies to enhance efficacy in OSCC's complex environment. • Despite limitations, ongoing research into CAR-T therapy shows promising future prospects for OSCC treatment.
No takes yet. Share an insight, caveat, or question.
Madar et al. (2024) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: